ASH 2017 | MRD assessment: NGS vs. flow cytometry
One of the controversies surrounding the use of minimal residual disease (MRD) is the optimal technique for its assessment. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Prof. Landgren gives his take on the best method for MRD assessment. Ola Landgren, MD, PhD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses robustness, reproducibility and sensitivity. He highlights the current limitations of even our best methods of MRD measurement. In addition, he discusses the clinical process of determining MRD in multiple myeloma (MM).
Get great new content delivered to your inboxSign up